A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $31 to $33
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $30 to $36
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating
Pfizer Analyst Ratings
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $45
Pfizer (PFE) Gets a Buy From Cantor Fitzgerald
Citi Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
Hold Recommendation on Pfizer Amid Promising but Early Stage Cancer Cachexia Drug Development
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Goldman Sachs Adjusts Price Target on Pfizer to $32 From $34
Pfizer Analyst Ratings
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $30
Jefferies Sticks to Its Buy Rating for Pfizer (PFE)
Pfizer's Leadership Stability and Activist Investor Watch: A Hold Rating Analysis